LML 134

Drug Profile

LML 134

Alternative Names: LML134

Latest Information Update: 03 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Circadian rhythm sleep disorders
  • Phase I Sleep disorders

Most Recent Events

  • 28 Jul 2017 Phase-II clinical trials in Circadian rhythm sleep disorders in USA (unspecified route) (NCT03141086)
  • 10 May 2017 Novartis plans a phase II trial for Circadian rhythm sleep disorders (NCT03141086)
  • 06 Jan 2015 Preclinical trials in Sleep disorders in Germany(PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top